# AON Investment

> AON Investment is a VC fund in Seoul backing Health Care, Biotechnology and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 9
- Last investment: Mar 2026
- Lead investor: 33%
- Last updated: Aug 2026
- Website: https://aoninvest.co.kr

AON Investment is a venture capital firm that invests in technology companies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Biotechnology | 3 | 33% |
| Medical | 2 | 22% |
| Software | 2 | 22% |
| Artificial Intelligence | 2 | 22% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 11% |
| Series A | 1 | 11% |
| Series B | 1 | 11% |
| Series C | 1 | 11% |
| Funding Round | 1 | 11% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 6 | 67% |
| United States | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mediwhale | Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $13.3M | Series C | Mar 27, 2026 |  |
| CLUSH | Clush is an AI and cloud infrastructure company that builds enterprise software to help organizations develop, deploy, and manage AI systems. The company offers cloud-native services and products, enabling customers to build, manage, and collaborate on cloud-based applications and data. Clush provides products such as Clush Kube MLOps, AIgovernance platforms, AI agents, hybrid cloud infrastructure, and enterprise collaboration tools for industries including finance, manufacturing, and public sector organizations | $26.3M | Venture - Series Unknown | Jan 27, 2026 |  |
| Orum Therapeutics | Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M | Post-IPO Equity | Dec 18, 2025 |  |
| MediMabBio | MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M | Series B | Oct 24, 2025 |  |
| Kailos Lab | Kailos Lab is an AI-driven deep-tech company focused on materials research and development. It builds data and AI-powered platforms that accelerate the discovery, analysis, and development of new materials. By integrating computational models with laboratory data, the company aims to improve R&D efficiency and support innovation in advancedmaterials and industrial applications. | $2.2M | Seed | Apr 23, 2025 |  |
| CLUSH | Clush is an AI and cloud infrastructure company that builds enterprise software to help organizations develop, deploy, and manage AI systems. The company offers cloud-native services and products, enabling customers to build, manage, and collaborate on cloud-based applications and data. Clush provides products such as Clush Kube MLOps, AIgovernance platforms, AI agents, hybrid cloud infrastructure, and enterprise collaboration tools for industries including finance, manufacturing, and public sector organizations | $14.3M | Series A | Nov 20, 2024 |  |
| Rznomics | Rznomics Inc. is a South Korean biotechnology company developing RNA-based gene therapies for cancer, genetic, and neurodegenerative diseases. The company focuses on trans-splicing ribozyme and circular RNA technologies, with pipeline candidates targeting liver cancer, glioblastoma, Alzheimer’s disease, and retinal disorders. | $15.2M | Venture - Series Unknown | Sep 06, 2024 |  |
| Allround Doctors | Allround Doctors is a digital healthcare startup that develops digital medical devices for cancer patients. | $5.1M | Series A | Aug 06, 2024 |  |
| Novorex | Novorex specializes in the development of molecule drugs targeting oncology and neurology diseases. | $8.9M | Convertible Note | Nov 21, 2023 |  |

9 of 9 investments shown.

## Co-investors
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 6 deals together
- [IMM Investment](https://shizune.co/investors/profile/imm-investment) — VC Fund, 3 deals together
- [BNH Investment](https://shizune.co/investors/profile/bnh-investment) — VC Fund, 2 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 2 deals together
- [Hana Ventures](https://shizune.co/investors/profile/hana-ventures) — VC Fund, 2 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does AON Investment invest in?

AON Investment invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AON Investment last invest?

The most recent investment recorded for AON Investment closed in Mar 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co